Half a century of computer methods and programs in biomedicine: A bibliometric analysis from 1970 to 2017.

BACKGROUND AND OBJECTIVE: Computer Methods and Programs in Biomedicine (CMPB) is a leading international journal that presents developments about computing methods and their application in biomedical research. The journal published its first issue in 1970. In 2020, the journal celebrates the 50th anniversary. Motivated by this event, this article presents a bibliometric analysis of the publications of the journal during this period (1970-2017). METHODS: The objective is to identify the leading trends occurring in the journal by analysing the most cited papers, keywords, authors, institutions and countries. For doing so, the study uses the Web of Science Core Collection database. Additionally, the work presents a graphical mapping of the bibliographic information by using the visualization of similarities (VOS) viewer software. This is done to analyze bibliographic coupling, co-citation and co-occurrence of keywords. RESULTS: CMPB is identified as a leading and core journal for biomedical researchers. The journal is strongly connected to IEEE Transactions on Biomedical Engineering and IEEE Transactions on Medical Imaging. Paper from Wang, Jacques, Zheng (published in 1995) is its most cited document. The top author in this journal is James Geoffrey Chase and the top contributing institution is Uppsala U (Sweden). Most of the papers in CMPB are from the USA followed by the UK and Italy. China and Taiwan are the only Asian countries to appear in the top 10 publishing in CMPB. A keyword co-occurrences analysis revealed strong co-occurrences for classification, picture archiving and communication system (PACS), heart rate variability, survival analysis and simulation. Keywords analysis for the last decade revealed that machine learning for a variety of healthcare problems (including image processing and analysis) dominated other research fields in CMPB. CONCLUSIONS: It can be concluded that CMPB is a world-renowned publication outlet for biomedical researchers which has been growing in a number of publications since 1970. The analysis also conclude that the journal is very international with publications from all over the world although today European countries are the most productive ones.

Intravenous lacosamide in clinical practice-Results from an independent registry.

PURPOSE: This non-interventional study was conducted to evaluate the efficacy and tolerability of intravenous lacosamide (LCM-iv) under routine conditions in daily clinical practice as a prospective registry. METHODS: Patients with any type of seizure or epilepsy syndrome were recruited in 16 neurological and neuropediatric centers in Germany if the treating physician decided to administer LCM-iv for any reason. Observation time per patient was 10 days with daily documentation of LCM-iv administration, type and frequency of seizures, currently used drugs and doses, and adverse events. Treatment efficacy, tolerability, and handling of LCM-iv were assessed using a five-step scale. RESULTS: In 119 patients treating physicians classified epilepsies as focal in 66.1% and generalized in 17.4% (16.5% unclassifiable). Most common etiologies of seizures were tumors (36.1%) and cerebrovascular diseases (21.8%). Reasons for LCM-iv treatment included preparation for surgery (25.2%), convulsive (24.4%) and non-convulsive (18.5%) status epilepticus (SE), series of seizures (16.0%), gastrointestinal causes (5.9%), and acute seizures (4.2%). The median dose of LCM-iv was 300mg per day. In 45 of 64 patients (70.3%) with SE or series of seizures, epileptic activity ceased during observation time. Five patients showed abnormalities in ECG prior to the infusion and one patient afterwards, but during infusion no abnormalities were reported. Treating physicians rated efficacy and tolerability as very good or good in 77.6% and 93.1% of patients, respectively. CONCLUSIONS: This large and independent multicenter registry on the use of LCM-iv in clinical practice demonstrates that LCM-iv is well-tolerated and highly efficacious when given in emergency situations, including patients experiencing SE. It is advisable to perform an electrocardiogram prior to LCM-iv administration.